

Financial Disclosure

For: Paul W. Armstrong, Distinguished University Professor, University of Alberta, Founding Director, Canadian VIGOUR Centre, University of Alberta, Edmonton, Alberta **

Updated: September, 2018

Monetary amounts are on an annual basis

Company/(Companies):	Period of Support	Name of Project	1) A research grant or contract from this Company generates revenue for the University of Alberta	2) A research grant or contract from this Company partially supports my research projects	3) Educational activities or lectures for this Company generates revenue for the University of Alberta		4) Consulting or other services for this company generates personal income		5) I receive significant personal royalties from this Company	6) I have equity in this Company	Comments
					<\$10K	>\$10K	<\$10K	>\$10K			
Sanofi-aventis Recherche & Développement	2012 – 2018	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome (ODYSSEY Outcomes)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
AstraZeneca	2015 – 2017	New Concepts in Acute Coronary Syndromes: Beyond 2000	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Merck	2015 – 2017	New Concepts in Acute Coronary Syndromes: Beyond 2000	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Merck	2016 to present	VeriCiguaT gLObal study in patients with heart failure and Reduced ejection fraction (VICTORIA)	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Bayer	2016 – 2017	New Concepts in Heart Failure and Atrial Fibrillation: Beyond 2000	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Novartis	2016 – 2017	New Concepts in Heart Failure and Atrial Fibrillation: Beyond 2000	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Bayer	2017 – 2019	Consultant	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Boehringer Ingelheim	2017 to present	STRategic Reperfusion in elderly patients Early After Myocardial Infaction (STREAM-II)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	

Company/(Companies):	Period of Support	Name of Project	1) A research grant or contract from this Company generates revenue for the University of Alberta	2) A research grant or contract from this Company partially supports my research projects	3) Educational activities or lectures for this Company generates revenue for the University of Alberta		4) Consulting or other services for this company generates personal income		5) I receive significant personal royalties from this Company	6) I have equity in this Company	Comments
					<\$10K	>\$10K	<\$10K	>\$10K			
Bayer	2018 – 2020	A Randomized Parellel-Group, Placebo Controlled, Double-Blind, Multi-Center Confirmatory Trial to Evaluate the Efficacy and Safety of the Oral sGC Stimulator on Physical Limitations in Patients with Heart Failure and Preserved Ejection Fraction (VITALITY)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
CSL Limited	2018 – 2022	A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome (AEGIS II)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	

**** Please note this document should be placed in the context that Dr. Armstrong is working 0.5 FTE at the University. In accordance with the American Heart Association conflict of interest policies.**